Trials / Active Not Recruiting
Active Not RecruitingNCT05440786
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 1 Year – 39 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Orally |
| DRUG | Irinotecan | IV |
| DRUG | Temozolomide | Orally |
Timeline
- Start date
- 2022-09-20
- Primary completion
- 2025-01-15
- Completion
- 2026-12-01
- First posted
- 2022-07-01
- Last updated
- 2026-04-13
- Results posted
- 2026-03-12
Locations
29 sites across 7 countries: United States, Australia, France, Germany, Italy, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05440786. Inclusion in this directory is not an endorsement.